We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

41 hedge funds and large institutions have $6.86M invested in AIM ImmunoTech in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

14% more funds holding

Funds holding: 36 → 41 (+5)

40% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 10

53% less capital invested

Capital invested by funds: $14.7M → $6.86M (-$7.88M)

Holders
41
Holders Change
+5
Holders Change %
+13.89%
% of All Funds
0.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
6
Reduced
10
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$1.09M
2
Citadel Advisors
Citadel Advisors
Florida
+$63.6K
3
VF
Virtu Financial
New York
+$58.3K
4
Jane Street
Jane Street
New York
+$24K
5
Verition Fund Management
Verition Fund Management
Connecticut
+$21K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$531K
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$107K
3
WG
Winton Group
United Kingdom
-$103K
4
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$94K
5
Millennium Management
Millennium Management
New York
-$64K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$1.88M -$531K -3,434 -14%
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.84M -$4.02K -26 -0.1%
BlackRock
3
BlackRock
New York
$767K +$9.43K +61 +0.7%
Renaissance Technologies
4
Renaissance Technologies
New York
$649K +$1.09M +7,058 New
Geode Capital Management
5
Geode Capital Management
Massachusetts
$343K – – –
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$277K -$107K -694 -19%
BCM
7
Bridgeway Capital Management
Texas
$199K -$30.9K -200 -8%
Verition Fund Management
8
Verition Fund Management
Connecticut
$149K +$21K +136 +9%
State Street
9
State Street
Massachusetts
$148K – – –
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
$107K – – –
Northern Trust
11
Northern Trust
Illinois
$82K +$464 +3 +0.3%
RJFSA
12
Raymond James Financial Services Advisors
Florida
$45K – – –
Citadel Advisors
13
Citadel Advisors
Florida
$37K +$63.6K +411 New
Rockefeller Capital Management
14
Rockefeller Capital Management
New York
$36K – – –
SWM
15
SeaCrest Wealth Management
New York
$35K -$7.73K -50 -11%
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$35K +$2.47K +16 +4%
VF
17
Virtu Financial
New York
$35K +$58.3K +377 New
Bank of New York Mellon
18
Bank of New York Mellon
New York
$25K – – –
HighTower Advisors
19
HighTower Advisors
Illinois
$22K -$26.3K -170 -41%
CAPTRUST Financial Advisors
20
CAPTRUST Financial Advisors
North Carolina
$18K – – –
LPL Financial
21
LPL Financial
California
$15K – – –
WG
22
Winton Group
United Kingdom
$14K -$103K -669 -81%
Bank of America
23
Bank of America
North Carolina
$14K -$928 -6 -4%
Jane Street
24
Jane Street
New York
$14K +$24K +155 New
Millennium Management
25
Millennium Management
New York
$12K -$64K -414 -76%
1
2

AIM Hedge Fund Activity: Q4 2021 in Review

41 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q4 2021, worth a combined $6.86M — down 53% from $14.7M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new AIM positions and 4 closed out — a net gain of 5 holders — while 6 added to existing stakes and 10 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.09M. The largest seller was Morgan Stanley, cutting an estimated $531K.

  • 41 institutional investors held AIM ImmunoTech (AIM) as of Q4 2021, up from 36 in Q3 2021.
  • Funds reported $6.86M of AIM ImmunoTech stock for Q4 2021, down 53% quarter-over-quarter.
  • 9 funds opened new AIM ImmunoTech positions in Q4 2021 and 4 closed out, a net change of +5 holders.
  • The largest AIM ImmunoTech buyer in Q4 2021 was Renaissance Technologies, an estimated $1.09M added.
  • The largest AIM ImmunoTech seller in Q4 2021 was Morgan Stanley, an estimated $531K sold.

Based on aggregated 13F filings for Q4 2021.